Tag: report

1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025

SEATTLE, June 12, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (Nasdaq: DDI) (“DoubleDown” or the “Company”) today announced the pricing of an underwritten secondary offering of 4,347,827 American Depositary Shares (the “ADSs”), each ADS representing 0.05 common share of the Company (“Common Shares”), at a public offering price of $8.50 per ADS by STIC Special Situation Diamond Limited (the “Selling Shareholder”). The Selling Shareholder has granted the underwriters a 30-day option to purchase up to 652,173 additional ADSs at the public offering price, less underwriting discounts and commissions. The offering consists entirely of the ADSs to be sold by the Selling Shareholder and will not change the number of Common Shares that are outstanding.

Large-scale testing by Fluence and CSA Group shows Gridstack Pro 5000 system, delivering up to 5.6 MWh in a 20-foot enclosure, surpassing current and emerging safety standards 

Board Committed to Protecting Long-Term Value for All Stockholders

VALENCIA, Spain, June 12, 2025 (GLOBE NEWSWIRE) -- Turbo Energy S.A. (Nasdaq: TURB) (“Turbo Energy” or the “Company”), a global provider of leading-edge, AI-optimized solar energy storage technologies and solutions, today announced that it has been granted a new patent for its innovative system designed to integrate energy storage and expand photovoltaic generation in upstream installations. The patented system provides a unique method for enhancing energy efficiency and flexibility in self-consumption solar power systems—particularly those configured to prevent surplus energy from being injected into the electrical grid.

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte^®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.

Potential strategic alliance aims to transform residential real estate accessibility and transaction efficiency through exclusive integration of MiiX’s proprietary platform across La Rosa’s network